Background and Objectives: Optical imaging to guide cancer resections is rapidly transitioning into the operating room. However, the sensitivity of this technique to detect subclinical disease is yet characterized. The purpose of this study was to determine the minimum range of cancer cells that can be detected by antibody-based fluorescence imaging.
Optical imaging technologies often utilize fluorescent light in the near-infrared (NIR) range (700-900 nm), which provides favorable depth of tissue penetration and minimizes tissue autofluorescence by reducing background scattering. 4 Regardless of the specific modality used, an important consideration in optical imaging is tumor specificity of the optical probe, which can improve resolution of the tumor for in vivo imaging. For example, fluorescently labeled monoclonal antibodies that target ligands overexpressed in tumors are ideal probes due to their high affinity and specificity for the target antigen, and they can be administered systemically.
However, the ability of these optical probes to identify small nests of subclinical disease, not otherwise visible with the naked eye, is not well characterized. Traditionally, a 1 cm 3 tumor (1 × 10 9 cells) is generally considered to be the amount of tumor that is clinically detectable, 5 but the true limit of sensitivity of fluorescent optical probes is not well defined. Therefore, the primary objective of this study is to quantify this tumor detection threshold by utilizing cetuximab, a monoclonal antibody to epidermal growth factor receptor (EGFR), conjugated to the NIR fluorescent dye molecule IRDye800CW
(IRDye800CW-N-hydroxysuccinimide ester, LI-COR Biosciences, Lincoln, NE). IRDye800CW is a NIR probe with a broad absorption (778 nm) and emission (794 nm) spectrum, and has been shown to be nontoxic in humans. [6] [7] [8] EGFR is overexpressed in head and neck squamous cell carcinoma (HNSCC), with over 90% of tumors overexpressing the receptor. [9] [10] [11] In fact, several cancer types are known to over express EGFR, including breast, pancreas, and colon; thus, it serves as a versatile and reliable probe target. [12] [13] [14] [15] [16] Therefore, in this study, multiple cancer
types were tested to demonstrate the adaptability and application of this probe to detect subclinical disease in various patient populations.
| MATERIALS AND METHODS

| Reagents
Anti-EGFR antibody, cetuximab, (Erbitux, ImClone, New York, NY; 152 kDa) was supplied at 2 mg/mL. The fluorescent probe, IRDye800CW, (IRDye800CW-N-hydroxysuccinimide ester; LI-COR Biosciences) was supplied as a GMP-compliant reagent. The University of Alabama at Birmingham Vector Production Facility performed the conjugation reaction to prepare the cetuximab-IRDye800CW. Antibodies were incubated with IRDye800CW in 1.00 M potassium phosphate buffer (pH 9.0) for 2-h at room temperature. Desalting spin columns (Pierce Biotechnology, Rockford, IL) removed the unconjugated dye. A final dye:protein ratio of 1.5-2.0 was determined using spectrophotometry.
To produce lower concentrations of cetuximab-IRDye800CW, stock agent (2 mg/mL) was diluted in 1X PBS (21-040-CV, Mediatech, Inc., Manassas, VA). 
| Cell lines and tissue culture
| Animal models
Female nude athymic mice, aged 4-6 weeks (Charles River Laboratories, Hartford, CT), were used for the studies. All experiments and euthanasia procedures were performed in accordance with the 
| Imaging devices
The Pearl Impulse (LI-COR Biosciences) is a NIR closed-field imaging system with a cooled charge-coupled camera that is optimized for IRDye800CW spectrum. A Xenogen IVIS 100 bioluminescenceimaging (BLI) device (PerkinElmer, Waltham, MA) was used to localize and quantify the bioluminescent signal from implanted Luc+ cells in the tumor boluses.
| Titer of cetuximab-IRDye800CW probe concentration
To assess the minimum cetuximab-IRDye800CW availability needed to fluorescently localize disease, serially diluted amounts of cetuximab- 
| Calculation of theoretical minimum number of cells detectable
The theoretical minimum number of cells detectable was determined by interpolation to find the cell count when TBR = 1, the threshold of positive fluorescence contrast. 19 A theoretical detection range was calculated for each cell line. The interpolation was drawn between loaded cell count at a TBR > 1 ± SD to the loaded cell count at TBR < 1 ± SD. That is, the assessed linear regression was determined at cell count = TBR > 1 + SD to cell count = TBR < 1 + SD, and cell count = TBR > 1 − SD to cell count = TBR < 1 − SD.
| Statistics
Calculated TBRs were assessed with student T-tests between cohorts to determine statistical significance. 
| Minimum number of tumor cells detectable
Next, disease quantity exposed to cetuximab-IRDye800CW was varied to determine the lowest fluorescently active cell titer required for disease detection (Fig. 1B) . BLI was used as the gold standard for tumor localization and normalization of tumor fluorescence signal. In 
| Effect of incubation time on disease detection
To determine the effect of prolonged probe exposure time on (Fig. 4A) . The 8.6 × 10 −2 µM cetuximab-IRDye800CW dose was the minimum dose to sufficiently localize disease (Fig. 4B) . Next, the determination of minimum numbers of cells required for detection was re-examined (Fig. 4C ). As shown (Fig. 4D) , 2LMP incubated for 24-h positively identified disease at 1.0 × 10 6 (TBR: 21.9; P < 0.001), Using this antibody-based method, fluorescence contrast delivers a more sensitive and specific approach when compared to a surgical and pathological evaluation. 20 When compared to standard 31 Nonetheless,
Pearl does represent an effective prototype for the utility of both current and future NIR devices. However, Pearl could be rapidly integrated into patient care as a post-resection, specimen-imaging tool.
While Pearl may not function to provide real-time resection guidance, it may improve disease eradication by assessing disease margins more quickly than histopathologic methods. A limitation of fluorescence detection as a whole includes local, non-specific fluorescence due to increased photon scattering events near disease that may limit precise localization. This results in a fluorescent halo illuminating non-diseased tissues. While the perfect probe will produce disease specific fluorescence, the minimal, collaterally resected tissue with non-ideal agents is much less than that resected when disease is evaluated on palpation and visual aspects alone. As a result, decreased excision of non-diseased tissue may improve post-resection functionality. 1 In conclusion, we showed cetuximab-IRDye800CW has the potential to detect subclinical islands of disease in the surgical setting.
Further study is required for each tumor type to realize the specific, beneficial gain this technology offers compared to contemporary resection. 1 Results from the current study support the use of this modality to augment complete resection rates and decrease morbidity and mortality in EGFR-positive disease.
